Our product development activities start with the end in mind. Intellectual property and diagnostic tests enable the delivery of personalized healthcare. Concentrating on high impact disorders, IntegraGen deployed its arsenal of internal resources to identify new loci, disease haplotypes, and disease-associated genes. Alone and with partners, IntegraGen utilizes this intellectual property to deliver commercialized offerings and services.
Dr Bernard Courtieu spoke at the 3rd Meeting of the Pharmaceutical Industry in Barcelona. Date : November 5th, 2009.
His presentation focused on new approaches and business models to innovation for biotech markets.
More information : IESE Barcelona
7-10 September 2009 : Prof. Andreas Ziegler, University of Lübeck, made a presentation on methods for Evaluating clinical validity in single affected offspring trio families. at 54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) conference in Essen (Germany)
9 june 2009 : Bernard Courtieu, CEO of IntegraGen, attended the AMIPS* conference on "Drug development for personalised medicine". His presentation focused on biomarkers development for Neurology.
*AMIPS : Association des Médecins des Industries des Produits de Santé (French association of Medical doctors of health industry products)
